On September 9, 2020 Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, reported that it has closed its previously announced registered direct offering to certain institutional investors of 8,865,000 shares of common stock at a price of $0.79 per share (Press release, Apricus Biosciences, SEP 9, 2020, View Source [SID1234564822]). The Company also closed its previously announced concurrent private placement to the investors of unregistered warrants to purchase up to 6,648,750 shares of common stock. The warrants have an exercise price of $0.84 per share of common stock, will be exercisable six months from the date of issuance and will expire five years following the initial date of exercise.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

After deducting the placement agent’s fees and offering expenses, the Company received net proceeds of approximately $6.2 million. Seelos intends to use the net proceeds from the offering for general corporate purposes and to advance the development of its product candidates.

Roth Capital Partners acted as the sole placement agent for the offering.

A shelf registration statement on Form S-3 (File No. 333-221285) relating to the shares of common stock issued in the registered direct offering was previously filed with the Securities and Exchange Commission (the "SEC") on November 2, 2017, amended on December 1, 2017 and declared effective by the SEC on December 7, 2017. Such shares were offered only by means of a prospectus. A prospectus supplement and the accompanying prospectus relating to and describing the terms of the registered direct offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the registered direct offering may also be obtained by contacting Roth Capital Partners, LLC, 888 San Clemente Drive, Newport Beach, California 92660, by calling (800) 678-9147 or by e-mail at [email protected].

The unregistered warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act"), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Act or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

On September 9, 2020 Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, reported that Lloyd M. Segal, President and Chief Executive Officer, will participate in a virtual fireside chat at the Morgan Stanley Annual Global Healthcare Conference on Tuesday, September 15 at 10:15 a.m. ET (Press release, Repare Therapeutics, SEP 9, 2020, View Source [SID1234564843]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside can be accessed in the Investor section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 30 days following the fireside chat.

On September 9, 2020 Caris Life Sciences, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, reported that Brian J. Brille, Vice Chairman of the Company, will participate in a fireside chat at the 18th Annual Morgan Stanley Global Healthcare Conference Thursday, Sept. 17, 2020, at 9:30 a.m. Eastern time (Press release, Caris Life Sciences, SEP 9, 2020, View Source [SID1234564875]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Brille will provide an overview of Caris’ business, along with its suite of market-leading molecular profiling offerings, and discuss recent corporate growth initiatives that position Caris to further extend its leadership reach in the market. Thomas Parker, Senior Vice President and Chief Financial Officer at Caris, will be available for Q&A.

Attendees who would like to schedule a one-on-one meeting with Caris executives may do so by contacting their Morgan Stanley representative.

On September 9, 2020 Merck, a leading science and technology company, reported the € 59 million expansion of its HPAPI and ADC manufacturing capacity at its facilities near Madison, Wisconsin , USA (Press release, Merck & Co, SEP 9, 2020, https://www.prnewswire.com/news-releases/merck-anuncia-a-expansao-de-eur-59-milhoes-na-fabricacao-de-conjugado-de-anticorpo-medicamento-856068008.html [SID1234564902]). The investment will allow for the large-scale manufacture of increasingly potent compounds for therapies with the potential to treat cancer. Completion is scheduled for mid-2022, and about 50 full-time jobs are expected to be created from 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Merck is expanding its ability to manufacture ADCs, which are an emerging class of drugs created with the highly specific goal of destroying cancer cells while preserving healthy ones.
"ADCs have seen incredible growth in the past decade, and regulatory approval in recent years demonstrates their promise as a targeted therapy," said Andrew Bulpin , director of Process Solutions, Merck’s Life Science business. "With over 35 years of experience in this area, we were pioneers in the development and manufacture of biological products, conjugation processes and small molecules. This investment reinforces our commitment to working with innovators to make new treatments available to patients more quickly and efficient".

Merck ‘s new 6,500 m 2 office building will be one of the largest dedicated HPAPI manufacturing facilities, specifically designed to handle single digit nanogram occupational exposure limit materials. The project is an addition to the company’s Madison campus , which was the first commercial ADC facility in North America designed to handle highly active materials. The new building will join the Merck campus based in St. Louis, Missouri , USA, specializing in bioconjugation for ADC, active pharmaceutical ingredients and the manufacture of excipients and adjuvants.

ADCs are an emerging class of highly specific drugs, created with the goal of destroying cancer cells while preserving healthy ones. Today there are only nine ADCs approved globally. However, the ADC industry is experiencing solid growth and is expected to reach € 13 billion in 2030 1 .

While ADCs can provide many benefits compared to other therapeutic options, they also present a unique set of challenges. Its development is complex, requiring rigorous containment infrastructure, and its structural exceptionality requires knowledge in a series of different technologies for small and large molecules, as well as analytical resources. Due to these challenges, more than 70% of ADC projects are outsourced to organizations specialized in their development and manufacture 2 .

With more than 35 years of experience in the development and manufacture of small molecules, biological products and ADC technologies, Merck offers extensive experience in clinical and commercial manufacturing. The company’s comprehensive service portfolio combines the stages of drug development and production, from pre-clinical to commercial, from a single source. This consolidation helps to reduce risks and streamlines the process of obtaining therapies for patients more quickly.

All Merck communications are distributed by email, in addition to being available on the company’s website. Visit www.merckgroup.com/subscribe to register online, change your options or stop your service.

On September 9, 2020 Exscientia, the world-leading, clinical-stage Artificial Intelligence (AI) drug discovery company and Huadong Medicine, the leading Chinese pharmaceutical company, reported that the companies have entered into a co-development partnership to accelerate the discovery of breakthrough small-molecule therapeutics targeted at innovative approach to oncology (Press release, Exscientia, SEP 9, 2020, View Source [SID1234565052]). The first project selected in partnership is focused on transcription control of DNA damage response genes, to treat patients with defective DNA damage repair mechanism, leading to high mutation frequency, as seen is in patients with ovarian cancer and breast cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under this collaboration, the pharmatech Exscientia and Huadong will share responsibilities, with Exscientia applying its advanced Centaur Chemist(TM) AI platform to design new molecules against project specific objectives and Huadong Medicine applying its China based experimental and managerial capabilities to generate data and progress Exscientia’s AI design in a rapid closed-loop cycle.

Huadong Medicine Co., Ltd (SZSE 000963), ranked in the top 10 Chinese pharmaceutical companies by Forbes 2020, with more than 10,000 employees and over US $4 Billion annual revenue. The co- development partnership will support both Huadong’s strategy to introduce new medicines in key markets and Exscientia’s aims to advance AI-designed innovative medicines globally.

"This collaboration marks a key step for Huadong on its journey to become an innovation-based pharmaceutical company. We are pleased to work with Exscientia and are fully committed to make this collaboration a success.", said Lyu Liang, Chairman of Huadong.

Professor Andrew Hopkins, CEO of Exscientia, said, "We are very excited to enter the partnership with Huadong Medicine. This innovative partnership provides strategic benefits to Huadong Medicine and Exscientia. We see this as the start of a long-term productive relationship to accelerate novel drug discovery and bring benefits to patients around the globe."